Hobbs Group Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-24
Closed -$2.37K 630
2024
Q3
$2.37K Hold
24
﹤0.01% 562
2024
Q2
$2.23K Buy
+24
New +$2.15K ﹤0.01% 534
2023
Q4
$2.14K Buy
+24
New +$1.78K ﹤0.01% 461

Other funds holding XBI

Hobbs Group Advisors's XBI Position: Q4 2024 in Review

Hobbs Group Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2024, closing a stake of 24 shares — an estimated $2.37K sold.

Hobbs Group Advisors first reported a position in XBI in Q4 2023 and held it in 3 quarters. The position peaked at $2.37K in Q3 2024. 738 funds tracked by Wall St. Rank hold XBI as of Q4 2024.

  • Hobbs Group Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2024 after selling out during the quarter.
  • Hobbs Group Advisors sold 24 State Street SPDR S&P Biotech ETF shares in Q4 2024, an estimated $2.37K.
  • Hobbs Group Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2023 and held it in 3 quarters.
  • Hobbs Group Advisors's State Street SPDR S&P Biotech ETF position peaked at $2.37K in Q3 2024.
  • 738 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2024.

Based on Hobbs Group Advisors's 13F filing for Q4 2024, filed 12 Feb 2025.